Aclaris Announces Pricing of Initial Public Offering
October 06 2015 - 9:25PM
Aclaris Therapeutics, Inc. today announced the pricing of its
initial public offering of 5,000,000 shares of its common stock at
a price to the public of $11.00 per share. The shares have been
approved for listing on The NASDAQ Global Select Market and are
expected to begin trading under the ticker symbol "ACRS" on October
7, 2015. All of the common stock is being offered by Aclaris. In
addition, Aclaris has granted the underwriters a 30-day option to
purchase up to 750,000 additional shares of common stock at the
initial public offering price. The offering is expected to close on
October 13, 2015, subject to customary closing conditions.
Jefferies LLC and Citigroup Global Markets Inc. are acting as
joint book-running managers for the offering. William Blair &
Company, L.L.C. is acting as a co-manager.
The offering will be made only by means of a prospectus. A copy
of the final prospectus, when available, may be obtained from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
(877) 547-6340 or by email at prospectus_department@jefferies.com,
or Citigroup Global Markets Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by
telephone at (800) 831-9146, or by email at
prospectus@citi.com.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
October 6, 2015.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage specialty
pharmaceutical company focused on identifying, developing, and
commercializing novel drugs to address unmet needs in dermatology.
Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania.
CONTACT: Aclaris Contact
Frank Ruffo
Chief Financial Officer
484-324-7933
investors@aclaristx.com
Investor Contact
Patricia L. Bank
Westwicke Partners
Managing Director
415-513-1284
patti.bank@westwicke.com
Media Contact
Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024